ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Trading 06-25 11:12:08 EDT

10.40

+0.15

+1.46%

High10.67	Low10.39	Vol8.39K
Open10.60	D1 Closing10.25	Amplitude2.73%
Mkt Cap93.26M	Tradable Cap10.61M	Total Shares8.97M
T/O87.35K	T/O Rate0.82%	Tradable Shares1.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":10.4,"timestamp":1782399983214,"preClose":10.25,"halted":0,"volume":8389,"delay":0,"changeRate":0.014634146341463448,"floatShares":1019940,"shares":8967700,"eps":-18.6,"marketStatus":"Trading","change":0.15,"latestTime":"06-25 11:12:08 EDT","open":10.6,"high":10.67,"low":10.39,"amount":87353.532874,"amplitude":0.027317,"askPrice":11,"askSize":113,"bidPrice":10.39,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-18.6,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782417600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":10.25,"preHourTrading":{"tag":"盘前","latestPrice":10.14,"preClose":10.25,"latestTime":"04:00 EDT","volume":4,"amount":40.56,"timestamp":1782374423644,"change":-0.11,"changeRate":-0.010732,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":10.25,"preClose":10.24,"latestTime":"16:10 EDT","volume":589,"amount":6037.25,"timestamp":1782331805291,"change":0.01,"changeRate":0.000977,"amplitude":0},"volumeRatio":2.175807},"requestUrl":"/m/hq/s/PMN/tweets","defaultTab":"tweets","newsList":[{"id":"2645209892","title":"Promis Neurosciences Price Target Maintained with a $18.00/share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645209892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645209892?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:02","pubTimestamp":1782298920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings(END) Dow Jones NewswiresJune 24, 2026 07:02 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641433885","title":"ProMIS Neurosciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641433885","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641433885?lang=en_us&edition=fundamental","pubTime":"2026-06-08 23:47","pubTimestamp":1780933620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 11:47 ET (15:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638913266","title":"ProMIS Neurosciences to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2638913266","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638913266?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:13","pubTimestamp":1779977631,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences to present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, 11:40 a.m.–12:10 p.m. ET.Virtual Alzheimer’s R&D Day hosted by Wolfe Research set for June 4, 2026, 8:30 a.m.–9:00 a.m. ET; invitation-only.Presentation planned for June 15, 2026 at the H.C. Wainwright Neuro Perspectives Expert Summit in New York.One-on-one meetings slated at the BIO International Convention in San Diego on June 22–25, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL8l9Djd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","PMN","IE00BKPKM429.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","BK4585","LU0314104364.USD","LU2210149790.SGD","BK4112","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4139","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638662691","title":"ProMIS Neurosciences to Participate in Upcoming Conferences in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2638662691","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638662691?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:13","pubTimestamp":1779977580,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May  28, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303024/0/en/ProMIS-Neurosciences-to-Participate-in-Upcoming-Conferences-in-June.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637887318","title":"ProMIS Neurosciences shareholders approved 900,000-share increase to 2025 incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2637887318","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637887318?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:33","pubTimestamp":1779309182,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences held its annual shareholder meeting on May 20, 2026.Shareholders backed an amendment to the 2025 Stock Option and Incentive Plan, increasing the share pool available for issuance under the plan by 900,000 shares; the amendment became effective upon that approval.The appointment of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026 was ratified.Director nominees were elected to serve until the 2027 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Ex","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL83cGxq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636584668","title":"ProMIS Neurosciences initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636584668","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636584668?lang=en_us&edition=fundamental","pubTime":"2026-05-20 18:26","pubTimestamp":1779272762,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $40 price target Published first on TheFly – the ultimate source f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN","BK4139","BRKL","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071800","title":"MindWalk reports 10 partner-owned antibody programs in active Phase 1-3 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636071800?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:55","pubTimestamp":1779112530,"startTime":"0","endTime":"0","summary":"MindWalk Holdings released a report in May 2026 attributing more than 20 drug candidates that reached clinical trials to antibody discovery work conducted at its facilities.Ten partner-owned programs were described as active in Phase 1 to Phase 3 trials across oncology, immunology, neurology, infectious disease.Examples cited included Annexon’s ANX005 in Phase 3 for Guillain-Barré syndrome, argenx’s ARGX-119 in Phase 2/3 for congenital myasthenic syndrome, ProMIS Neurosciences’ PMN310 in Phase 1b for Alzheimer’s disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2hykl3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANNX","BK4139","PMN","BK4121","HYFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635532020","title":"Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635532020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635532020?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:50","pubTimestamp":1778881809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN) and Evolent Health (EVH) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-promis-neurosciences-pmn-evolent-health-evh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-promis-neurosciences-pmn-evolent-health-evh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","LU0053671581.USD","PMN","BK4581","BK4588","EVH","XLV","LU0128526141.USD","LU0029874061.USD","HCSG","XBI","BK4167","BK4139","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212795","title":"ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634212795?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:34","pubTimestamp":1778592888,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc reports results for the quarter ended March 31 - Earnings SummaryProMIS Neurosciences Inc PMN.OQ reported a quarterly adjusted loss of $1.26 per share for the quarter ended Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P1Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634185532","title":"ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634185532","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634185532?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:57","pubTimestamp":1778583441,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of $(5.25) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52479480/promis-neurosciences-q1-eps-1-26-beats-1-48-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290396","title":"ProMIS Neurosciences Q1 FY26 net loss widens to $8.24 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634290396?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:30","pubTimestamp":1778581852,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences posted a net loss of $8.2 million, widening from $7.3 million a year earlier.Operating loss widened to $8.6 million as operating expenses climbed to $8.6 million, led by R&D spending of $7 million.Cash and cash equivalents rose to $63.8 million following a February private placement that brought in $75.5 million in gross up-front proceeds.PRECISE-AD Phase 1b trial of Alzheimer’s candidate PMN310 is fully enrolled with 144 participants, with a blinded 6-month interim safety and biomarker analysis expected in early Q3 2026.Cash runway is expected to fund operations through 2027, including completion of the PRECISE-AD trial, with unblinded 12-month top-line data anticipated in early 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL50gcF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","NDAQ","BK4585","LU2095319765.USD","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU2210149790.SGD","BK4112","PMN","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634302290","title":"ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634302290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634302290?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:30","pubTimestamp":1778581800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA29ZSPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633468435","title":"ProMIS Neurosciences Inc  expected to post a loss of $1.48 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633468435","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633468435?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:47","pubTimestamp":1778255228,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc  expected to post a loss of $1.48 a share - Earnings Preview ProMIS Neurosciences Inc PMN.OQ PMN.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1XY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629898315","title":"ProMIS Neurosciences director Patrick D. Kirwin acquires $45,320 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629898315","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629898315?lang=en_us&edition=fundamental","pubTime":"2026-04-24 09:25","pubTimestamp":1776993940,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences director Patrick D. Kirwin reported purchase of 4,000 common shares at $11.33.Holdings held via Patrick D. Kirwin Professional Corp rose to 4,653 common shares.Kirwin also reported indirect ownership of 305 common shares held by his spouse.Kirwin reported direct beneficial ownership of 5,135 common shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL8FV4sM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ProMIS Neurosciences director Patrick D. Kirwin acquires $45,320 common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629783038","title":"Fact Check: No, the Whoosh High-Speed Rail Debt Was Not Repaid in Two Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2629783038","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629783038?lang=en_us&edition=fundamental","pubTime":"2026-04-21 17:59","pubTimestamp":1776765548,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-There are more than 25 posts on Instagram [archive], Facebook, Threads, TikTok, and YouTube claiming that Indonesian President Prabowo Subianto will pay off the debt for the Jakarta-Bandung Whoosh high-speed rail within two months. This narrative has been circulating since April 11, 2026.The repayment was claimed to be made through the Danantara Investment Management Agency to avoid burdening the State Budget . \"Finally, the Whoosh Train debt will be paid off within two months by Danantara,\" the accounts wrote.Is it true that Danantara paid off the debt for the Whoosh high-speed rail in two months without using the state budget?","market":"sh","thumbnail":"https://statik.tempo.co/data/2026/04/20/id_1469597/1469597_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/04/20/id_1469597/1469597_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2099512/fact-check-no-the-whoosh-high-speed-rail-debt-was-not-repaid-in-two-months","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2099512/fact-check-no-the-whoosh-high-speed-rail-debt-was-not-repaid-in-two-months","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4585","LU2272731600.USD","MBG","MBG.AU","GB00BDT5M118.USD","LU2211815571.USD","LU1992135472.HKD","LU1992135399.USD","BK4198","BK7104","PMN","BK4139","BK4588","COO","COO.AU","BK7016","STT","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443714","title":"ProMIS Neurosciences to present at Bloom Burton Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443714","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627443714?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:32","pubTimestamp":1776079940,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences will present at Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026, 2:30-3:00 pm ET.Conference runs April 21-22, 2026, at Metro Toronto Convention Centre in Toronto.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL9cZDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622875668","title":"ProMIS Neurosciences Inc  expected to post a loss of $1.91 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622875668","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622875668?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:22","pubTimestamp":1774624963,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc  expected to post a loss of $1.91 a share - Earnings Preview ProMIS Neurosciences Inc PMN.OQ PMN.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1H0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000666","title":"ProMIS Neurosciences Files $200 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000666","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000666?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:48","pubTimestamp":1774475323,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences  late Wednesday filed a shelf registration statement with US regulators for the potential sale of up to $200 million of securities, to be offered from time to time.The filing covers common shares, preferred shares, subscription receipts, debt securities, warrants and units.The company said it intends to use the net proceeds for the clinical development of PMN310 therapeutic candidate, for working capital and general corporate purposes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000314","title":"ProMIS Neurosciences files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000314?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:25","pubTimestamp":1774473926,"startTime":"0","endTime":"0","summary":"17:24 EDT ProMIS Neurosciences (PMN) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-files-200m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-files-200m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622719007","title":"ProMIS Neurosciences Inc - May Offer up to $50 Mln Common Shares Under Sales Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622719007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622719007?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:23","pubTimestamp":1774473813,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D11W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":-0.0135},{"period":"1month","weight":-0.0674},{"period":"3month","weight":-0.3232},{"period":"6month","weight":0.3368},{"period":"1year","weight":-0.1555},{"period":"ytd","weight":0.5004}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0166},{"period":"3month","weight":0.1366},{"period":"6month","weight":0.0622},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0753}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.492325},{"month":2,"riseRate":0.5,"avgChangeRate":0.1186},{"month":3,"riseRate":0,"avgChangeRate":-0.161081},{"month":4,"riseRate":0.5,"avgChangeRate":0.06597},{"month":5,"riseRate":0,"avgChangeRate":-0.137867},{"month":6,"riseRate":0,"avgChangeRate":-0.128692},{"month":7,"riseRate":0.333333,"avgChangeRate":0.096733},{"month":8,"riseRate":0,"avgChangeRate":-0.185569},{"month":9,"riseRate":0.5,"avgChangeRate":-0.048217},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042317},{"month":11,"riseRate":0,"avgChangeRate":-0.242658},{"month":12,"riseRate":0.5,"avgChangeRate":-0.058437}],"exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}